Previous reports suggest that resistance to mitoxantrone in different tumor cell lines is unrelated to the overexpression of pglycoprotein. In order to determine the role of p-glycoprotein in the cellular pharmacology of mitoxantrone flow cytometry and confocal microscopy were used to study two human myeloid leukemia cell lines selected for resistance to mitoxantrone (HL-60MX2) and doxorubicin (HL-60DOX). To optimize the detection of intracellular mitoxantrone, we determined the maximum excitation (607 nm) and emission (684 nm) wavelength by fluorescence spectroscopy. The modified flow cytometric conditions using 568.2 nm laser emission for excitation and a 620 nm long pass filter for fluorescence collection resulted in a 1-log increase in sensitivity, compared with standard 488-nm laser excitation. Uptake and retention of mitoxantrone in the presence of verapamil, a calcium channel blocker known to inhibit p-glycoprotein, were analyzed. Our results showed no change in uptake and retention of the drug in pglycoprotein-negative mitoxantrone-resistant HL-60MX2 cells and in its sensitive parental line, HL-60s. In contrast, 3.1-and 2.4-fold increases were found in uptake and retention of mitoxantrone in p-glycoprotein-positive cells (HL-60DOX) incubated with verapamil. Confocal microscopy of intracellular drug distribution demonstrated reduced nuclear uptake, which could be reversed by verapamil, in HL-60DOX. A characteristic punctate pattern was observed for the intracytoplasmic drug distribution in HL-60DOX and HL-60MX2 cells and was partially modified by the presence of verapamil in HL-60DOX cells. Verapamil increased cytotoxicity of mitoxantrone two-fold in HL-60DOX cells, 1.4-fold in HL-60MX2, and had no effect in HL-60s. Our study demonstrates that the cellular pharmacology of mitoxantrone is affected by p-glycoprotein and can be reversed at least in part by verapamil. Other mechanisms of resistance however, seem to play a determinant role in the modulation of mitoxantrone cytotoxicity.
Introduction
Mitoxantrone is an anticancer anthraquinone drug 1, 2 that has shown therapeutic efficacy comparable with that of standard induction and salvage treatment regimens in advanced breast cancer, 3 acute leukemia, 4, 5 non-Hodgkin's lymphoma, 6 and chronic myeloid leukemia in blastic transformation. 7 Although mitoxantrone is structurally similar to anthracycline doxorubicin, it has an improved tolerability profile, 8 and the mechanism of action appears to be quite different. Like other anthracyclines, mitoxantrone intercalates into DNA and causes DNA-protein cross-links and protein-associated double-stranded and single-stranded breaks in the DNA. In addition, this drug is able to stabilize the DNA topoisomerase II cleavable complex and to prevent DNA synthesis. 8 The development of cellular resistance to anticancer drugs greatly limits the activity of cancer chemotherapy against malignant tumors. In this regard, overexpression of p-glyco-protein is particularly important because it confers cross-resistance to several structurally unrelated drugs. 9 The mechanisms of action of mitoxantrone resistance are not well known. Although mitoxantrone seems to select for a unique drugresistance phenotype, some cross-resistance with anthracyclines has been shown in vitro. 10, 11 Human colon carcinoma, 12 leukemia 13 and gastric carcinoma 14 cell lines selected by continuous exposure to increasing concentrations of mitoxantrone had no p-glycoprotein overexpression. Clinical cross-over studies have not demonstrated complete crossresistance between mitoxantrone and doxorubicin, 15, 16 providing rationale for the use of mitoxantrone in diseaserelapsed patients following anthracycline treatment. In contrast to these reports, mitoxantrone like the anthracyclines, has also been shown to select for cells exhibiting the MDR phenotype mediated by p-glycoprotein overexpression. 17 Furthermore, a resistance mechanism associated with enhanced efflux involving a pathway distinct from the MDR-1-encoded p-glycoprotein has also been reported. 18 Flow cytometry and confocal laser microscopy have been successfully used to analyze cellular pharmacology and the intracellular distribution of anthracyclines based on their fluorescence emission after laser excitation. This method provides a powerful tool to evaluate the role of p-glycoprotein in the cellular pharmacology of anthracylines and in the development of MDR in various systems in vitro 19, 20 and in vivo. 21, 22 Although mitoxantrone shares only part of its chemical structure with other anthracyclines, like doxorubicin, it has a planar electron-rich chromophore of a polycyclic dye, which is responsible for its fluorescent properties.
In this study, we used a fluorimetric method to evaluate the intracellular content of mitoxantrone in order to clarify the influence of p-glycoprotein on the cellular pharmacology of mitoxantrone and in the development of MDR. Uptake and retention of mitoxantrone were evaluated in two human cell lines selected for resistance to mitoxantrone (HL-60MX2, pglycoprotein negative) and doxorubicin (HL-60DOX, p-glycoprotein positive) and their drug-sensitive parent cell line (HL60s, p-glycoprotein negative) in the presence of verapamil, a calcium channel blocker known to inhibit MDR possibly by interfering with p-glycoprotein function. 23 Cytotoxicity assays in the presence and absence of verapamil were also performed to analyze the role of p-glycoprotein in protecting cells from mitoxantrone cytotoxicity. Lastly, to evaluate the cellular pharmacology of mitoxantrone better, we studied the different patterns of intracellular distribution using confocal laser scanning microscopy with optical sectioning capability. In this study, we provide evidence that mitoxantrone is a substrate for p-glycoprotein and that higher intracellular concentrations of mitoxantrone in p-glycoprotein-positive cells incubated in the presence of verapamil are associated with increased cytotoxicity, circumventing, at least in part, p-glycoproteinmediated MDR.
The human acute myeloid leukemia HL-60s and its mitoxantrone-selected HL-60MX2 cell lines were generously provided by Dr Graydon Harker (VA Medical Center, Salt Lake City, UT, USA). The multiple myeloma parent cell line 8226/S and its doxorubicin-resistant mutants 8226/DOX6 and 8226/DOX40 were kindly provided by Dr WS Dalton (University of Arizona, Tucson, AZ, USA). Those cell lines were grown in RPMI 1640 supplemented with 10% FCS, 1% penicillin, 1% streptomycin and 1% L-glutamine (all from GIBCO-BRL, Gaithersburg, MD, USA). Doxorubicin-resistant selected HL-60DOX cells were grown in IMDM supplemented with 10% FCS, 1% penicillin, 1% streptomycin and 1% Lglutamine. Cell cultures were maintained at 37°C in a humidified 5% CO 2 atmosphere.
RNA extraction and reverse transcriptase PCR (RT-PCR)
RNA was isolated according to the acid-guanidium-phenolchloroform method. 24 RT-PCR was performed as previously reported. 25 
Antibody staining
For the study of p-glycoprotein MoAb 4E3 (kindly provided by Dr R Arceci, Dana-Farber Cancer Center, Boston, MA, USA) was used as previously described. 26 
Flow cytometry
Flow cytometric measurements were performed with a duallaser FACS Vantage (Becton Dickinson, Mountain View, CA, USA). The krypton/argon spectrum laser (Coherent, Mountain View, CA, USA) emits several lines in the orange and red areas of the light spectrum, all suitable for mitoxantrone binding studies, but the orange line at 568.2 nm (150 mW) was chosen as the best combination of high efficiency of excitation (% of maximum), wide range of collectable drug fluorescence emission, and availability of filters to allow the measurement of drug emission free of interference from incident light. For the 4E3 MoAb, an argon ion laser (Spectra Physics, Mountain View, CA, USA) operating at 488 nm and 15 mW was used, and detection light was collected through a 530/30 nm band pass filter. Data acquisition and analysis were performed with the Lysys II software (Becton Dickinson) and results were expressed as D values according to the Kolmogorov-Smirnov statistic.
Cell uptake and retention studies Cells were incubated at the concentration of 2 × 10 6 /ml in medium plus FCS 5% with or without verapamil (10 M) for 2 h at 37°C with mitoxantrone at the concentration of 5 g/ml. For uptake studies, aliquots of 5 × 10 5 cells were taken after 15, 30, 60, 90 and 120 min of incubation. Cells were washed in ice-cold PBS without Ca 2+ or Mg 2+ , resuspended in 0.5 ml ice-cold PBS, and mitoxantrone fluorescence was measured within 5 min. For retention studies, at the end of a 2 h exposure, every sample was washed twice in ice-cold PBS and resuspended for 2 h in fresh medium, with or without 10 M verapamil. Cells were incubated at 37°C, and aliquots of cells were analyzed at 15, 30, 60, 90 and 120 min in the same conditions used for the uptake studies. Experiments were performed in triplicate, and a representative experiment is shown. The uptake and retention were calculated by dividing the median level fluorescence channel, after 2 h of incubation with verapamil, by the fluorescence signal of the cells incubated with the drug alone, measured at the same time point. The level of drug fluorescence increase corrected for autofluorescence was expressed as the mean of three experiments.
Cytotoxicity (MTT assay)
Drug cytotoxicity in vitro was assessed for each cell line by using the MTT dye reduction assay (Sigma Chemical Company, St Louis, MO, USA). This technique relies on converting MTT (3,(4,-dimethylthiazol-2-yl)-2-5 diphenyl tetrazolium bromide) to a red formazan product by reductive enzymes present only in metabolically viable cells. Hence, the quantitation of insoluble formazan was possible by dissolving it in a lysing buffer and measuring the optical density of each sample with a microplate spectrophotometer (Molecular Devices USA, Menlo Park, CA, UA) at a 570 nm wavelength. Cells (135 l) were plated in 96-well microassay culture plates (2 × 10 4 cells/well) and grown for 24 h at 37°C in a CO 2 incubator. Drugs were then added to the wells (15 l) to achieve a final drug concentration of 0.025 to 5 g/ml (eight wells were used for each different concentration). The plates were incubated at 37°C in a 5% CO 2 incubator for 1 h. Cells were then resuspended in fresh medium and incubated for 72 h. Wells containing culture medium in the presence or absence of verapamil were used as controls. When incubation was complete, 25 l of the stock solution of MTT dye in a 0.9% aqueous NaCl solution was added to each well to achieve a final concentration of 0.5 g/ml. The plates were incubated at 37°C in a CO 2 incubator for 4 h. Subsequently, 85 l of lysing buffer (20% solution of SDS in DMF and water (1:1, pH 4.7)) was added, and the cells were incubated for an additional 24 h at 37°C in a 5% CO 2 incubator. The optical density of each well was then measured with a microplate spectrophotometer (Molecular Devices USA) at a wavelength of 570 nm. The percentage of cell viability was calculated using the following equation: % cell viability = (mean optical density of treated wells/ mean optical density of control wells) × 100
The viability values were plotted against the drug concentration used, and the ID 50 was calculated from the curve. Experiments were repeated at least three times.
Laser confocal microscopy
An upright version of a Zeiss (New York, NY, USA) confocal laser scanning microscope equipped with a He/Ne laser (543-nm emission, power 5 mW) and a LSMv2.0 software, was used. Signals were collected by a photomultiplier through a 590-nm long pass filter. Digitized images were transmitted to a MAC-based image analysis system through a GPIB interface using BDS-LSM software (Biological Detection Systems, Pittsburgh, PA, USA). IPLab software was used for image processing (Signal Analytics, Vienna, VA, USA). Teflon-coated glass microscopy slides (Cel-Line Associates, Newfield, NJ, USA) with 10 wells, each 7 mm in diameter and containing 10 l, were used. Cells adhering to the microscope slide were analyzed for mitoxantrone distribution under oil immersion microscopy. HL-60s, HL-60DOX and HL-60MX2 were incubated in the presence of mitoxantrone either with or without verapamil as described above for uptake study. Drug distribution was recorded within 5 min after 30 and 90 min of incubation with the drugs.
Results

Mitoxantrone fluorescence properties
The excitation spectrum of mitoxantrone in aqueous solution ( Figure 1a) showed peak excitation at 607 nm and demonstrated that excitation at 488 nm was only 6% of the maximum. This greatly limits the usefulness of the 488 nm line of the Argon laser for pharmacological distribution studies of mitoxantrone, specially at low drug concentrations. The emission spectrum of mitoxantrone obtained with a SPF-500TM spectrofluorimeter (SLM Instrument, Urbana, IL, USA) showed a relative fluorescence emission at 568.2 nm, which is 20-fold higher than the emission obtained at 488 nm (Figure 1b) . This maximum was also confirmed by absorption spectrophotometry (data not shown). The 568.2 nm wavelength used for drug binding studies by flow cytometry resulted in a 1-log improvement in sensitivity, compared with the 488 nm wavelength, which was also confirmed by fluorescence spectroscopy showing a 10-fold higher emission level when mitoxantrone was excited at 567 nm rather than at 488 nm.
Analysis of MDR-1 mRNA by PCR amplification using MDR-1-specific primers 
Flow cytometric analysis of p-glycoprotein expression
To relate protein expression to MDR-1 mRNA, we measured p-glycoprotein of these cell lines by flow cytometry. Figure 3 shows that HL-60DOX cells incubated with MoAb 4E3 were strongly fluorescent (D value of 0.98), indicating the presence Excitation spectra of mitoxantrone in aqueous solution. Sensitivity at 568.2 nm was six-fold higher than at 488 nm (a). Emission spectra of mitoxantrone excited at 568.2 nm (---) and 488 nm (--------) (b). Fluorescence maximum was 20-fold higher after excitation at 568.2 nm as compared with 488 nm. shows the results of uptake and retention studies in HL-60DOX cells after exposure of 5 g/ml of mitoxantrone alone or in combination with verapamil 10 M. Cells incubated in drug-free medium with or without verapamil, were used as controls. In HL-60DOX cells, incubation with mitoxantrone and verapamil resulted in a 3.1-fold increase in mitoxantrone uptake when compared with the same cells incubated in the absence of verapamil. During efflux studies, the presence of verapamil resulted in a 2.4-fold increase in mitoxantronerelated fluorescence retention maintaining the same level reached during uptake in the presence of mitoxantrone.
Effect of verapamil on mitoxantrone uptake and retention in HL-60MX2 and HL-60s cells
The cellular pharmacology of mitoxantrone in HL-60MX2 and HL-60s cells was studied as described above. No increase in Figure 3 P-glycoprotein expression in HL-60s (B), HL-60MX2 (D) and HL-60DOX (F) cells using flow cytometry analysis with the MoAb 4E3 and a secondary goat-anti-mouse FITC-conjugated antibody. An isotype IgG2a was used as control (A, C, E). The x-axis had a range of 4 log. the intracellular content of mitoxantrone was observed in the presence of verapamil during uptake and retention studies for HL-60MX2 ( Figure 5 ) and HL-60s ( Figure 6 ).
Cytotoxicity studies
The MTT dye reduction assay was used to determine the cytotoxicity of mitoxantrone in p-glycoprotein-positive and p-glycoprotein-negative cell lines. Resistant index (RI) is expressed as a ratio of the ID 50 for HL-60MX2 or HL-60DOX cells vs HL-60s cells (Table 1) . HL-60MX2 and HL-60DOX were more resistant than HL-60s cells (RI 28.9 and 15.9, respectively). In HL-60s, mitoxantrone cytotoxicity was not modified in the presence of verapamil (ID 50 0.49 ± 0.03 without verapamil vs ID 50 0.50 ± 0.02 with verapamil) and was only partially reduced for HL-60MX2 (1.4-fold) (ID 50 14 ± 0.7 without verapamil vs ID 50 10 ± 1.0 with verapamil). Mitoxantrone cytotoxicity in p-glycoprotein-positive HL-60DOX cells increased approximately two-fold by concomitant incubation with verapamil (ID 50 7.8 ± 0.4 without verapamil vs ID 50 4.2 ± 0.2 with verapamil). Verapamil alone showed no toxicity in any cell lines tested (data not shown).
Confocal microscopy
Optical section of interphase HL-60s cells (Figure 7a and b) revealed a predominantly cytoplasmic and perinuclear deposition of mitoxantrone after 30 min of incubation (Figure 7a ) with an increased concentration within the nuclear structures after 90 min (Figure 7b ). Cytoplasmic mitoxantrone fluorescence was predominantly detected in a diffuse distribution pattern with partial accumulation in the perinuclear zone and the Golgi area. Intense staining was noticed in the nuclear membrane and in nucleolar-like structures. This intracellular distribution was not modified by verapamil (data not shown).
Figure 4
In vitro cellular uptake and efflux in human acute leukemia cell line HL-60s. 10 6 cells/ml were incubated for 120 min with 5 g/ml mitoxantrone with (--q--) and without (-----Ì-----) verapamil. After 120 min of uptake, every sample was reincubated in drug-free medium with (--q--, --s--) and without (-----r-----, -----Ì-----) verapamil for 120 min. Control experiments using medium alone and verapamil alone showed curve overlap.
Figure 5
In vitro cellular uptake and efflux in human acute leukemia cell line HL-60MX2. 10 6 cells/ml were incubated for 120 min with 5 g/ml mitoxantrone with (--q--) and without (-----Ì-----) verapamil for 120 min of uptake. Every sample was reincubated in drug-free medium with (--q--, --s--) and without (-----r-----, -----Ì-----) verapamil for 120 min. Control experiments using medium alone and verapamil alone showed curve overlap.
HL-60MX2 cells (Figure 7c and d) showed very low nuclear fluorescence, and no nuclear membrane staining was observed, as compared with HL-60s. We observed reduced cytoplasmic fluorescence with condensation of mitoxantrone in highly fluorescent cytoplasmic inclusions (Figure 7c ). The addition of verapamil did not result in modification of intracellular drug distribution in these cells (Figure 7d In vitro cellular uptake and efflux in human acute leukemia cell line HL-60DOX. 10 6 cells/ml were incubated for 120 min with 5 g/ml mitoxantrone with (--q--) and without (-----Ì-----) verapamil. After 120 min of uptake, every sample was reincubated in drugfree medium with (--q--, --s--) and without (-----r-----, -----Ì-----) verapamil for 120 min. Control experiments using medium alone and verapamil alone showed curve overlap. Table 1 In vitro cytotoxicity of mitoxantrone with and without verapamil in HL-60S, HL-60DOX and HL-60MX2 cells 
Discussion
Development of cellular resistance to anticancer drugs limits the activity of chemotherapy and is a pivotal clinical problem. The limited data available on mitoxantrone resistance suggest that this drug selects an atypical resistance profile and displays only partial cross-resistance with other intercalating agents. In tumor cell lines selected for mitoxantrone resistance, various mechanisms including changes in topoisomerase II, 27 different drug compartmentalization, 28 differences in glutathione Stransferase, 29 and increased p-glycoprotein 17 and non p-glycoprotein-mediated drug efflux 14 have been demonstrated either separately or in combination and are postulated to have a role in cross-resistance with other structurally unrelated drugs. Unlike the anthracyclines, vinca alkaloids and natural products that usually select for the MDR-1 phenotype, tumor cells selected for resistance to mitoxantrone do not always overexpress p-glycoprotein. However, p-glycoprotein-positive cell lines can be cross-resistant to mitoxantrone, 30 and agents that circumvent p-glycoprotein have been used to increase mitoxantrone cellular concentration in murine Friend leukemia 31 and cytotoxicity in p-glycoprotein-positive K562 cells. 32 These findings strongly suggest an involvement of p-glycoprotein in mechanisms of resistance to mitoxantrone, but the role of pglycoprotein in cellular pharmacology and cytotoxicity of mitoxantrone has not been well defined. Several reports have been published on the cellular pharmacology of mitoxantrone, but few have investigated the distribution of drug molecules within intact, living cells. 33 Smith et al 34 showed the feasibility of using confocal microscopy to analyze the subcellular distribution of mitoxantrone, but they obtained only low levels of mitoxantrone fluorescence in neutral aqueous solution with an excitation at 514 nm, as we also found ( Figure  1 ). Smith et al attempted to correct this problem by absorbing the drug on to a silica matrix and by using high intensity laser power with a high photomultiplier gain setting. In this study, we optimized the spectral conditions under which mitoxantrone uptake, retention and distribution were measured by using the 568.2 nm laser line for excitation and 620 nm long pass filter for fluorescence collection. These conditions did not require excessive laser power or a high voltage photomultiplier and resulted in a 1-log enhancement in sensitivity when compared with drug binding studies using 514 nm or lower wavelength excitation. Under these conditions, we were able to apply to mitoxantrone a reliable flow cytometric method that has been used extensively in cellular pharmacology of other anthracyclines, for which the 488 nm line laser is a suitable source for excitation. 19, 26, 35 Combining these methods with cytotoxicity studies, we demonstrated that verapamil could increase mitoxantrone uptake and retention in HL-60DOX cells that displayed the MDR phenotype related to the presence of p-glycoprotein and that an increase in mitoxantrone content was associated with a two-fold enhanced cytotoxic effect. We also studied HL-60MX2 cells to analyze the cellular pharmacology in a mitoxantrone-resistant and p-gly-
Figure 7
Confocal microscope analysis of mitoxantrone fluorescence distribution in optical section of interphase HL-60s cells. Mitoxantrone-related fluorescence was visualized live after 30 (a) and 90 (b) min. Mitoxantrone after 30 min was first detected in the cytoplasmic area with a diffuse pattern of distribution and a distribution in the nuclear membrane, and nucleolar-like structures were noticed after 90 min. In HL-60MX2 cells, mitoxantrone was present in highly fluorescent cytoplasmic inclusions, and a reduced distribution in the nuclear structures was also observed (c). This distribution was not modified by the presence of verapamil (d). Intracellular drug distribution after 90 min in HL-60DOX cells was minimal and mostly limited to the cytoplasm, with a punctate pattern localization (e). Incubation of the cells in the presence of verapamil determined a consistent increase in mitoxantrone accumulation and a diffuse pattern of cytosol distribution (f). Although this distribution was similar to that of HL-60s cells, highly fluorescent cytoplasmic inclusions still persist, indicating the possible coexistence of different mechanisms of resistance.
coprotein-negative cell line that was selected for resistance to mitoxantrone and is cross-resistant to other drugs that inhibit topoisomerase II. 27 In agreement with the results of Harker et al 13 we found no p-glycoprotein overexpression by PCR and MoAb in this cell line. As expected, uptake, retention and cytotoxicity of mitoxantrone in HL-60MX2 cells were minimally modified by verapamil.
Although this cytofluorometric approach reflects the intracellular mitoxantrone content in single cells, no information can be obtained by flow cytometry regarding the subcellular distribution of the drug. Therefore, confocal microscopy under optical conditions similar to those used in flow cytometry was used to study the intracellular drug distribution. Confocal microscopic images demonstrated the different patterns of mitoxantrone distribution in HL-60s cells (diffuse) and HL-60MX2 cells (punctate), confirming the involvement of a mechanism of resistance that increased trapping of the drug in intracellular organelles, primarily in the Golgi apparatus and in lysosomes. 34 Interestingly, in HL-60DOX cells, more than one mechanism of resistance seemed to be present as we observed both sequestration in highly fluorescent intracytoplasmic vesicles and restoration of a diffuse pattern of distribution when p-glycoprotein was blocked by verapamil. Both mechanisms of intracytoplasmic sequestration and p-glycoprotein probably facilitate cell survival by decreasing drug concentration in the cytosol and nucleoplasm, but only p-glycoprotein is able to reduce the total amount of drug-related fluorescence within the cell. Compared with the other two cell lines, HL-60DOX showed a consistent decrease of the mitoxantrone-related fluorescence. This decrease was observed in both flow cytometric and confocal microscopy studies and in both cases was reverted by simultaneous incubation with a p-glycoprotein blocker. However, increased levels in intracytoplasmic mitoxantrone were not accompanied by a comparable increase in its cytotoxicity. The lack of linear correlation between increase in drug-related fluorescence and cytotoxicity in the presence of a p-gp blocker, observed also for doxorubicin and idarubicin, 26 can be explained by the presence of additional mechanisms of resistance and especially by mechanisms that increase trapping of the drug in intracellular organelles as observed by confocal microscope. We also analyzed our cell lines for the presence of the multidrug resistance-associated protein MRP, 36 and LRP-56, 37 which are not reversed by verapamil 38, 39 but no differences were observed between sensitive and resistant cell lines (data not shown). Recently, we also suggested that expression of genes related to the bcl-2 family in HL-60 is altered during development of anthracycline resistance, 40 which further implicates multiple distinct mechanisms acting at various points in conferring resistance to chemotherapy. Confocal microscopy confirmed the increased intracellular mitoxantrone-related fluorescence in HL-60DOX cells when incubated in the presence of verapamil. A different pattern of intracellular mitoxantrone distribution was observed in sensitive and resistant cells, with cytoplasmic punctate distribution observed in HL-60MX2 and HL-60DOX cells. Despite this finding, blocking drug efflux alone was followed by only a partial sensitization of p-glycoprotein-positive cells to chemotherapy, indicating that p-glycoprotein represents only one of the mechanisms responsible for mitoxantrone resistance. Although we demonstrated a role of p-glycoprotein in the cellular pharmacology of mitoxantrone, different mechanisms including drug compartmentalization, changes in topoisomerase II, and drug detoxification may primarily contribute to the clinical onset of resistance to mitoxantrone.
We report herein a reliable method to study the cellular pharmacology and distribution of mitoxantrone within intact, living cells. Our results demonstrate that the blockade of pglycoprotein-related drug efflux increased the concentrations of mitoxantrone in p-glycoprotein-positive cells suggesting that mitoxantrone is a substrate for p-glycoprotein. However, cytotoxicity was only partially improved by a p-gp blocker and other mechanisms of resistance were reported. These observations suggest the presence of a complex cellular mechanism responsible for mitoxantrone resistance which include intracellular uptake and efflux, formation of membrane vesicles and drug compartmentalization.
